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1 Introduction
The human placenta secretes a variety of protein
hormones and steroids into the maternal circula-
tion; measurement of these is widely used as a
diagnostic marker of fetal wellbeing in both early
and late pregnancy [3, 9]. The recent identifica-
tion of a number of new specific placental proteins
with no known function [10] has provoked
considerable interest in their possible clinical
application in pregnancy. Notable among these are
pregnancy specific ßl glycoprotein (SP1) and
placental protein 5 (PP5). Maternal serum levels of
SP1 are related to the delivered weight of the
infant and can be used to identify intrauterine
growth retardation [4,7, 14, 23, 25, 26]. Placental
protein 5 is much less efficient in this respect [17]
but has great potential interest because of its
possible association with the coagulation system
[16, 20] and the fact that elevated levels may be
associated with pre-eclampsia [11], placental
abruption [21] and premature labor [22]. The
present study was designed to compare the clinical
usefulness of four placental proteins (hCG, hPL,
SP1 and PP5) in the prediction of fetal status at
delivery (weight and presence or absence of fetal
distress).
2 Materials and methods
Single blood samples were taken from 527 unse-
lected women with a singleton pregnancy between
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36 and 40 weeks gestation. The group included 27
patients with mild to moderate pre-eclampsia
(diastolic blood pressure 90—100 mm Hg with or
without proteinuria), seven with antepartum
hemorrhage and five who delivered a stillborn
child; the latter were excluded from the overall
analysis. Serum was stored at — 20 °C until assay.
The measurement of hCG, hPL, SP1 and PP5 was
performed by radioimmunoassay as described
previously [6, 7, 12, 16]. The results were analysed
by calculation of means and standard deviations
after logarithmic transformation of the data: The
latter were used for comparison of sub-population
by Student's t-test. The data were divided into
centiles and the sensitivity, predictive value and
specificity of each test were calculated in respect
of the diagnosis of intrauterine growth retardation
0300-5577/83/0011-0121$02.00
© by Walter de Gruyter & Co. - Berlin · New York
122 Obiekwe, at al., Placental proteins
Tab. I. Maternal circulating levels of hCG, hPL, SP1 and
PP5 at 36-40 weeks gestation in the population described






















































(IUGR) and fetal distress. Intrauterine growth
retardation was defined as an infant whose birth
weight was equal or less than the 10th centile of
the whole population in this study (2740 g). Fetal
distress was defined as an abnormal variation of
the fetal heart rate using cardiotography (early or
late deceleration including tachycardia > 160/min
or bradycardia < 120/min) and/or the presence of
fresh meconium in the amniotic fluid during labor;
neonatal asphyxia was defined as an APGAR score
of 6 or less at 1 minute.
3 Results
The median levels of hCG, hPL, SP1 and PP5 were
stable between 36 and 40 weeks; the mean values
of each protein for the total population is shown
in Tab. I. There was no difference in the levels of
hCG, hPL, Spl and PP5 in patients with pre-
eclampsia when compared to the whole popula-
tion (Tab. I). Only hPL showed a significant
association with growth retardation (Tab. II). The
sensitivity, predictive value and specificity of all
four proteins in the diagnosis of this condition are
shown in Tab. Ill, and again, only hPL showed a
sensitivity and predictive value which would be of
any clinical significance.
Both hCG and hPL were significantly decreased in
subjects whose infants developed fetal distress
during labor (Tabs. IV, V). The mean levels of all
four proteins were elevated in the group with
neonatal asphyxia (Tab. IV) but this was not
statistically Significant. The mean birthweight of
the group with fetal distress alone (3273 g) did not
differ from that in the population as a whole
(3303 g).
4 Discussion
This is the first study in which maternal serum
hCG, hPL, SP1 and PP5 have been examined in the
same obstetric population in late pregnancy. The
Tab. II. Maternal circulating levels of hCG, hPL, SP1 and PP5 at 36-40 weeks gestation in 54 subjects with a growth
retarded fetus (< 10th centile of population range) compared with 468 subjects delivering a fetus of normal weight
Birthweight groups
hCG (Mg/1)
Birthweight > 10th centile
Birthweight < 10th centile
hPL (mg/1)
Birthweight > 10th centile
Birthweight < 10th centile
SP1 (mg/1)
Birthweight > 10th centile
Birthweight < 10th centile
PP5 (Mg/1)
Birthweight > 10th centile




















10th centile 90th centile t value and propability (p)
of difference
Ü2 200*'5 t-1.4S(NS)
4.04 M2 t - 3.916 < p < 0.001)
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ins Inn t = 1.746(NS)JLUJ JÖU
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NS - not significant.
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present findings confirm numerous previous investigation. Opinion is divided on this subject,
observations to the effect that low maternal hPL some workers (including our own group) having
levels are associated with intrauterine growth shown an association [4, 7, 12, 23, 25], while
retardation [13]. Surprisingly, SP1 levels were others have not [8]. A possible explanation lies in
not found to be of great value in the present methodological differences. Thus the measurement
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_ True positive, both maternal serum placental protein levels and infant weight were at or below the 10th centile
of the whole population.
TN - True negative, both the maternal serum placental protein levels and infant weight above the 10th centile of the
whole population.
FP — False positive, the maternal serum placenta! protein levels were at or below the 10th centiie, but infant weight
was above the 10th centile.
FN - False negative, the maternal serum placental protein levels were above the 10th centile, but infant weight was
at or below the 10th centile.
Tab. VI. Circulating levels of hCG, hPL, SP1 and PP5 in relation to the condition of the infant at birth. The probabil-
























































t-value and probability (P) of difference
t = 2.339 (P = 0.03)
t = 1.506
t = 1.263
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Tab. V. Sensitivity, predictive value and specificity of a single determination of serum hCG and hPL at 36-40 weeks
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of hPL is a long-established routine technique
in this unit, while that of SP1 continues to be a
research procedure for which long-term quality
control data is not available. The absence of a
useful association between levels of PP5 or hCG
and birthweight is less surprising and is in general
agreement with previous studies [15, 17, 18, 24].
However, levels of hCG were related to the sex of
the fetus [1, 2, 5, 18, 19] and for a given sex are
better related to the delivered weight of the
infant [18], though this is not of practical clinical
significance.
The relation of hCG and hPL levels to fetal distress
is of some potential clinical importance, particu-
larly since the prediction of this complication
is not apparently a secondary result of the associa-
tion with growth retardation. Thus low hCG
and hPL appear to predict fetal distress in babies
of any weight. This observation indicates that
biochemical tests of placental function are not
simply a rather inefficient method of 'weighing'
the fetus in utero, soon to be replaced by ultra-
sound, but in fact reflect dynamic aspects of
placental function unrelated to the gross morpho-
logy of the fetus. This view is reinforced by the
fact that hCG levels, which are much less efficient
than hPL in the detection of IUGR, are more
closely associated than hPL wkh fetal distress
(Tab. IV).
Summary
The purpose of this study was to compare the clinical
usefulness of four placental proteins (hCG, hPL, SP1 and
PP5) in the prediction of fetal status at delivery. Single
blood samples were then taken from 527 unselected
women with singleton pregnancy between 36-40 weeks
gestation. The group included 27 patients with pre-
eclampsia, 7 with antepartum hemorrhage and 5 who
delivered a stillborn child; the latter were excluded from
the overall analysis. The measurement of serum hCG,
hPL, SP1 and PP5 was performed by radioimmunoassay.
The results were analysed by calculation of means and
standard deviations after logarithmic transformation for
the comparison of sub-populations. The median levels of
hCG, hPL, SP1 and PP5 were found to be stable between
36 and 40 weeks. There was no difference in the levels of
hCG, hPL, SP1 and PP5 in patients with pre-eclampsia
when compared to the whole population. Only hPL
showed a significant association with growth retardation.
Both hCG and hPL were significantly decreased in sub-
jects whose infants developed fetal distress during labor.
The mean birthweight in the fetal distress group alone
(3273 g) did not differ from that of the population as a
whole (3303 g).
This is the first study in which maternal serum hCG, hPL,
SP1 and PP5 have been examined in the same obstetric
population in late pregnancy. We demonstrated a clear
association between low maternal hPL levels and the
occurrence of intrauterine growth retardation, in agree-
ment with previous published reports. SP1 levels were not
related to intrauterine growth retardation. The absence of
a useful association between PP5 or hCG arid birthweight
is less surprising and is in general agreement with previous
studies. Low levels of hCG and hPL were associated with
the occurrence of fetal distress in labor; the association
was independent of delivered weight. This suggests that
these proteins reflect both the overall growth of the child
and dynamic aspects of fetal nutrition.
Keywords: Fetal distress in labor, intrauterine growth retardation, placental proteins (hCG, hPL, SP1, PP5).
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Zusammenfassung
Vergleichende Untersuchungen zur klinischen Verwertbar-
keit von 4 Plazentaproteinen im letzten Schwangerschafts-
trimester
Wir haben in dieser Untersuchung die Aussagekraft von
4 Plazentaproteinen (HCG, HPL, SPj und PP5) bezüglich
des fetalen Zustands zum Zeitpunkt der Geburt miteinan-
der verglichen. Dazu wurden Blutproben von 527 zufällig
ausgewählten Frauen mit Einzelschwangerschaften zwi-
schen der 36. und 40. Woche entnommen. In der Gruppe
waren 27 Patientinnen mit Präeklampsie, 7 mit Blutungen
in der Schwangerschaft und 5 Frauen mit einer Totgeburt;
letztere wurden in der Auswertung nicht berücksichtigt.
Die Serumkonzentrationen von HCG, HPL, SPj und
wurden mit Hilfe der RIA-Methode bestimmt. Wir berech-
neten Mittelwerte und Standardabweichungen nach loga-
rithmischer Transformation zwecks Vergleich der Unter-
gruppen. Die mittleren Konzentrationen von HCG, HPL,
SPi und P?5 waren zwischen der 36. und 40. Schwanger-
schaftswoche stabil. Ein Vergleich der HCG-, HPL-, SPr
und PPs-Werte zwischen der Präeklampsie-Gruppe und
dem Gesamtkollektiv ergab keinen Unterschied. Nur der
HPL-Spiegel zeigte einen signifikanten Zusammenhang
mit einer Wachstumsretardierung. Sowohl HCG wie auch
HPL waren bei den Patientinnen, deren Kinder unter der
Geburt ein fetales Distress-Syndrom entwickelten, signifi-
kant erniedrigt. Das mittlere Geburtsgewicht in der
Distress-Gruppe (3273g) zeigte keine deutliche Abwei-
chung von dem des Gesamtkollektivs (3303 g).
In der vorliegenden Untersuchung wurden zum ersten Mal
die mütterlichen Serumkonzentrationen von HCG, HPL,
SPi und P?5 im gleichen geburtshilflichen Kollektiv in
der Spätschwangerschaft gemessen. In Übereinstimmung
mit früheren Arbeiten konnten wir einen deutlichen
Zusammenhang zwischen niedrigen HPL-Spiegeln und
intrauteriner Wachstumsretardierung feststellen. SPj-
Konzentrationen ließen keine Beziehung zu intrauteriner
Wachstumsverzögerung erkennen. Weniger überraschend
und ebenfalls in Übereinstimmung mit früheren Veröf-
fentlichungen ist dagegen der fehlende Zusammenhang
zwischen PP5- sowie HCG-Spiegeln und dem Geburts-
gewicht. Niedrige HCG- und HPL-Werte korrelierten mit
dem Auftreten von fetalem Distress unter der Geburt,
wobei dieser Zusammenhang unabhängig vom Geburts-
gewicht war. Wir glauben, daß diese Proteine das gesamte
fetale Wachstum wie auch dynamische Aspekte fetaler
Ernährung widerspiegeln.
Schlüsselwörter: Fetales Distress-Syndrom unter der Geburt, intrauterine Wachstumsretardierung, Plazentaproteine
Resume
Une etude comparative de l'utilisation clinique de 4
proteines placentaires au cours du troisieme trimestre
Le but de cette etude est de comparer Futilite clinique
de 4 proteines placentaires (HCG, HPL, SPI et PP5)
pour la prevision de i'etät foetal a Faccouchement. Des
echantillons de sang ont ete preleves chez 521 femmes
non selectionnees ayant une grossesse unique entre
36 et 40 semaines. Ce groupe inclut 27 patientes pre-
eclamptiques, 7 hemorragies de la grossesse, et 5 morts-
nes, ces derniers ont ete exclus de l'analyse globale. La
mesure de HCG, HPL, SPI et PP5 a ete realisee par radio-
immunologie. Les resultäts ont ete analyses par le calcul
des deviations moyennes et standard apres transformation
logarithmique pour la comparaison de sous-populations.
Les taux moyens de HCG, HPL, SPI et PP5 ont ete
trouves stables entre 36 et 40 semaines. II n'y a pas de
differences dans les taux d'HCG, HPL, SPI et PP5 chez
les patientes pre-eclamptiques en comparaison de la
population d'ensemble. Seiil HPL montre unfe association
significative avec le retard de croissance. Et HCG et HPL
sont diminues de fäqon significative chez les sujets dont
les enfants ont developpe une souffrance foetale en cours
de travail. Le poids de naissance moyen dans le groupe
isole des souffrances foetales (3273 g) ne differe pas de
celui de la population globale (3303 g).
II s'agit de la premiere etude dans laquelle HCG, HPL, SPI
et PP5 seriques maternels ont ete doses dans la meme
population en fin de grossesse. Les auteurs önt demontre
une association evidente entre des taux d'HPL maternels
bas et la survenue d'un retard de croissance intra-uterin ce
qui est en accord avec les travaux publics auparavant. Les
taux de SPI ne sont pas lies au retard de croissance.
L'absence de liaison utilisable entre PP5 ou HCG et le
poids de naissance est mpins etonnante et est en accord
global avec les etudes anterieures; des taux bas d'HCG et
d'HPL sont associes avec la survenue d'une souffrance
foetale en cours de travail; la liaison est independante du
poids de naissance. Cela suggere que ces proteines sont le
reflet ä la fois de la croissance dans son ensemble de
l'enfant et ä la fois des aspects dynamiques de la nutrition
foetale.
Mots-cles: Proteines placentaires (HCG, HPL, SPI, 5), retard de croissance intra-uterin, souffrance foetale en cours
de travail.
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